Cryptococcosis in sarcoidosis: cryptOsarc, a comparative study of 18 cases

QJM. 2013 Jun;106(6):523-39. doi: 10.1093/qjmed/hct052. Epub 2013 Mar 19.

Abstract

Aim: To describe the main characteristics and the treatment of cryptococcosis in patients with sarcoidosis.

Design: Multicenter study including all patients notified at the French National Reference Center for Invasive Mycoses and Antifungals.

Methods: Retrospective chart review. Each case was compared with two controls without opportunistic infections.

Results: Eighteen cases of cryptococcosis complicating sarcoidosis were analyzed (13 men and 5 women). With 2749 cases of cryptococcosis registered in France during the inclusion period of this study, sarcoidosis accounted for 0.6% of all the cryptococcosis patients and for 2.9% of the cryptococcosis HIV-seronegative patients. Cryptococcosis and sarcoidosis were diagnosed concomitantly in four cases; while sarcoidosis was previously known in 14/18 patients, including 12 patients (67%) treated with steroids. The median rate of CD4 T cells was 145 per mm(3) (range: 55-1300) and not related to steroid treatment. Thirteen patients had cryptococcal meningitis (72%), three osteoarticular (17%) and four disseminated infections (22%). Sixteen patients (89%) presented a complete response to antifungal therapy. After a mean follow-up of 6 years, no death was attributable to cryptococcosis. Extra-thoracic sarcoidosis and steroids were independent risk factors of cryptococcosis in a logistic regression model adjusted with the sex of the patients.

Conclusions: Cryptococcosis is a significant opportunistic infection during extra-thoracic sarcoidosis, which occurs in one-third of the cases in patients without any treatment; it is not associated to severe CD4 lymphocytopenia and has a good prognosis.

Publication types

  • Multicenter Study
  • Review

MeSH terms

  • Adolescent
  • Adult
  • Antifungal Agents / therapeutic use
  • CD4 Lymphocyte Count
  • Cryptococcosis / complications*
  • Cryptococcosis / diagnosis
  • Cryptococcosis / drug therapy
  • Cryptococcosis / immunology
  • Female
  • Glucocorticoids / therapeutic use
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Male
  • Middle Aged
  • Opportunistic Infections / complications*
  • Opportunistic Infections / diagnosis
  • Opportunistic Infections / drug therapy
  • Opportunistic Infections / immunology
  • Prognosis
  • Retrospective Studies
  • Sarcoidosis / complications*
  • Sarcoidosis / drug therapy
  • Sarcoidosis / immunology
  • Young Adult

Substances

  • Antifungal Agents
  • Glucocorticoids
  • Immunosuppressive Agents